Avacta Group (AVCT) H2 2024 earnings summary

Executive summary

• Transitioned to a pure-play oncology biopharmaceutical company, divesting diagnostics to focus on the proprietary precision peptide drug conjugate platform.

• Achieved clinical proof of concept for the platform, with significant reduction in toxicities and efficacy in salivary gland cancer and soft tissue sarcoma.

• Lead program FAPDOX (AVA6000) completed phase 1A, showing strong safety and efficacy signals, especially in salivary gland cancer.

• Strategic AI-driven collaboration with Tempus to refine indication selection and drive smarter clinical trials.

• Strengthened leadership team with new CFO, CSO, and non-executive directors.

Financial highlights

• R&D investment of GBP 14.27 million in 2023, in line with expectations.

• Admin expenses rose to GBP 12.05 million from GBP 7.89 million, reflecting management changes and biotech transition.

• Loss from continuing operations was GBP 28.98 million, similar to prior year.

• Operating cash outflows increased to GBP 24.5 million due to elevated R&D and one-off realignment costs.

• Cash and equivalents at year-end 2024 were GBP 12.87 million, rising to GBP 17.3 million by April 2025 after divestment, extending runway into Q1 2026.

Outlook and guidance

• Cash runway extends into Q1 2026; long-term funding strategy remains a top priority.

• FAPDOX expansion cohort data in salivary gland cancer expected late 2025; triple-negative breast cancer data in H1 2026.

• FAP-Exatecan IND filing and phase I trial start anticipated in Q1 2026, with initial data by end of 2026.

• Third, undisclosed program aims for candidate selection in 2025 and IND in late 2026.

• Ongoing commercial analysis to optimize pricing and market entry, with orphan pricing expected for initial indications.